Kendra K Radtke1, Kelly E Dooley2, Peter J Dodd3, Anthony J Garcia-Prats4, Lindsay McKenna5, Anneke C Hesseling4, Radojka M Savic6. 1. Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA. 2. Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 3. School of Health and Related Research, University of Sheffield, Sheffield, UK. 4. Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 5. Treatment Action Group, HIV/TB Project, New York, NY, USA. 6. Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, CA, USA. Electronic address: rada.savic@ucsf.edu.
Abstract
BACKGROUND: Malnourished and young children are particularly susceptible to severe forms of tuberculosis and poor treatment response. WHO dosing guidelines for drugs for tuberculosis treatment are based only on weight, which might lead to systematic underdosing and poor outcomes in these children. We aimed to assess and quantify the population effect of WHO guidelines for drug-susceptible tuberculosis in children in the 20 countries with the highest disease burden. METHODS: We used an integrated model that linked country-specific demographic data at the individual level from the 20 countries with the highest disease burden to pharmacokinetic, outcome, and epidemiological models. We estimated tuberculosis treatment outcomes in children younger than 5 years following WHO guidelines (children are dosed by weight bands corresponding to the number of fixed-dose combination tablets [75 mg rifampicin, 50 mg isoniazid, 150 mg pyrazinamide]) and two alternative dosing strategies: one based on a proposed algorithm that uses age, weight, and available formulations, in which underweight children would receive the same drug doses as would normal weight children of the same age; and another based on an individualised algorithm without dose limitations, in which derived doses results in target exposure attainment for the typical child. FINDINGS: We estimated that 57 234 (43%) of 133 302 children younger than 5 years who were treated for tuberculosis in 2017 were underdosed with WHO dosing and only 47% of children would reach the rifampicin exposure target. Underdosing and subtherapeutic exposures were more common among malnourished children than among age-matched healthy children. The proposed dosing approach improved estimated rifampicin target exposure attainment to 62% and equalised outcomes by nutritional status. An estimated third of unfavourable treatment outcomes might be resolved with this dosing strategy, saving the lives of a minimum of 2423 children in these countries annually. With individualised dosing approaches, almost all children could achieve adequate exposure for cure. INTERPRETATION: This work shows that a simple change in dosing procedure to include age and nutritional status, requiring no additional measurements or new drug formulations, is one approach to improve tuberculosis treatment outcomes in children, especially malnourished children who are at high risk of mortality. FUNDING: Eunice Kennedy Shriver National Institute of Child Health and Human Development and UK Medical Research Council.
BACKGROUND: Malnourished and young children are particularly susceptible to severe forms of tuberculosis and poor treatment response. WHO dosing guidelines for drugs for tuberculosis treatment are based only on weight, which might lead to systematic underdosing and poor outcomes in these children. We aimed to assess and quantify the population effect of WHO guidelines for drug-susceptible tuberculosis in children in the 20 countries with the highest disease burden. METHODS: We used an integrated model that linked country-specific demographic data at the individual level from the 20 countries with the highest disease burden to pharmacokinetic, outcome, and epidemiological models. We estimated tuberculosis treatment outcomes in children younger than 5 years following WHO guidelines (children are dosed by weight bands corresponding to the number of fixed-dose combination tablets [75 mg rifampicin, 50 mg isoniazid, 150 mg pyrazinamide]) and two alternative dosing strategies: one based on a proposed algorithm that uses age, weight, and available formulations, in which underweight children would receive the same drug doses as would normal weight children of the same age; and another based on an individualised algorithm without dose limitations, in which derived doses results in target exposure attainment for the typical child. FINDINGS: We estimated that 57 234 (43%) of 133 302 children younger than 5 years who were treated for tuberculosis in 2017 were underdosed with WHO dosing and only 47% of children would reach the rifampicin exposure target. Underdosing and subtherapeutic exposures were more common among malnourished children than among age-matched healthy children. The proposed dosing approach improved estimated rifampicin target exposure attainment to 62% and equalised outcomes by nutritional status. An estimated third of unfavourable treatment outcomes might be resolved with this dosing strategy, saving the lives of a minimum of 2423 children in these countries annually. With individualised dosing approaches, almost all children could achieve adequate exposure for cure. INTERPRETATION: This work shows that a simple change in dosing procedure to include age and nutritional status, requiring no additional measurements or new drug formulations, is one approach to improve tuberculosis treatment outcomes in children, especially malnourished children who are at high risk of mortality. FUNDING: Eunice Kennedy Shriver National Institute of Child Health and Human Development and UK Medical Research Council.
Authors: Emmanuel Chigutsa; Marianne E Visser; Elizabeth C Swart; Paolo Denti; Sudeep Pushpakom; Deirdre Egan; Nicholas H G Holford; Peter J Smith; Gary Maartens; Andrew Owen; Helen McIlleron Journal: Antimicrob Agents Chemother Date: 2011-06-27 Impact factor: 5.191
Authors: Helen E Jenkins; Courtney M Yuen; Carly A Rodriguez; Ruvandhi R Nathavitharana; Megan M McLaughlin; Peter Donald; Ben J Marais; Mercedes C Becerra Journal: Lancet Infect Dis Date: 2016-12-08 Impact factor: 25.071
Authors: Gijs T J van Well; Berbe F Paes; Caroline B Terwee; Priscilla Springer; John J Roord; Peter R Donald; A Marceline van Furth; Johan F Schoeman Journal: Pediatrics Date: 2009 Impact factor: 7.124
Authors: A Bekker; H S Schaaf; H R Draper; L van der Laan; S Murray; L Wiesner; P R Donald; H M McIlleron; A C Hesseling Journal: Antimicrob Agents Chemother Date: 2016-03-25 Impact factor: 5.191
Authors: G K Russell; C S Merle; G S Cooke; E C Casas; M Silveira da Fonseca; P du Cros Journal: Int J Tuberc Lung Dis Date: 2013-12 Impact factor: 2.373
Authors: Peter J Dodd; Courtney M Yuen; Charalambos Sismanidis; James A Seddon; Helen E Jenkins Journal: Lancet Glob Health Date: 2017-09 Impact factor: 26.763
Authors: Elin M Svensson; Gunnar Yngman; Paolo Denti; Helen McIlleron; Maria C Kjellsson; Mats O Karlsson Journal: Clin Pharmacokinet Date: 2018-05 Impact factor: 6.447
Authors: Bryan J Vonasek; Kendra K Radtke; Paula Vaz; W Chris Buck; Chishala Chabala; Eric D McCollum; Olivier Marcy; Elizabeth Fitzgerald; Alexander Kondwani; Anthony J Garcia-Prats Journal: Expert Rev Respir Med Date: 2022-02-28 Impact factor: 4.300
Authors: Alvaro A Ordonez; Elizabeth W Tucker; Carolyn J Anderson; Claire L Carter; Shashank Ganatra; Deepak Kaushal; Igor Kramnik; Philana L Lin; Cressida A Madigan; Susana Mendez; Jianghong Rao; Rada M Savic; David M Tobin; Gerhard Walzl; Robert J Wilkinson; Karen A Lacourciere; Laura E Via; Sanjay K Jain Journal: J Clin Invest Date: 2021-03-01 Impact factor: 14.808
Authors: Elisa Lopez-Varela; Ahmed A Abulfathi; Natasha Strydom; Pierre Goussard; Abraham C van Wyk; Anne Marie Demers; Anneen Van Deventer; Anthony J Garcia-Prats; Johannes van der Merwe; Matthew Zimmerman; Claire L Carter; Jacques Janson; Julie Morrison; Helmuth Reuter; Eric H Decloedt; James A Seddon; Elin M Svensson; Rob Warren; Radojka M Savic; Véronique Dartois; Anneke C Hesseling Journal: J Antimicrob Chemother Date: 2022-05-29 Impact factor: 5.758
Authors: N A H Seneadza; S Antwi; H Yang; A Enimil; A Dompreh; L Wiesner; C A Peloquin; M Lartey; M Lauzardo; A Kwara Journal: Int J Tuberc Lung Dis Date: 2021-01-01 Impact factor: 2.373
Authors: Kendra K Radtke; Anneke C Hesseling; J L Winckler; Heather R Draper; Belen P Solans; Stephanie Thee; Lubbe Wiesner; Louvina E van der Laan; Barend Fourie; James Nielsen; H Simon Schaaf; Radojka M Savic; Anthony J Garcia-Prats Journal: Clin Infect Dis Date: 2022-04-28 Impact factor: 20.999
Authors: Tom G Jacobs; Elin M Svensson; Victor Musiime; Pablo Rojo; Kelly E Dooley; Helen McIlleron; Rob E Aarnoutse; David M Burger; Anna Turkova; Angela Colbers Journal: J Antimicrob Chemother Date: 2020-12-01 Impact factor: 5.790